Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Inogen Tidal Assist Ventilators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.
IPO Year: 2014
Exchange: NASDAQ
Website: inogen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/15/2024 | Mkt Perform → Outperform | William Blair | |
| 8/8/2023 | $15.00 → $8.00 | Overweight → Neutral | JP Morgan |
| 7/14/2023 | Buy → Hold | Needham | |
| 1/17/2023 | Outperform → Mkt Perform | William Blair | |
| 12/9/2021 | $47.00 | Hold → Buy | Needham |
| 11/8/2021 | $70.00 → $40.00 | Hold | Stifel |
| 11/5/2021 | $72.00 → $42.00 | Market Perform | SVB Leerink |
| 11/2/2021 | $71.00 → $45.00 | Underweight → Neutral | JP Morgan |
| 8/5/2021 | Overweight → Sector Weight | Keybanc |
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
3 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
3/A - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
10-Q - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
DEFA14A - Inogen Inc (0001294133) (Filer)
DEF 14A - Inogen Inc (0001294133) (Filer)
S-8 - Inogen Inc (0001294133) (Filer)
10-K - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced management will participate in the 24th Annual Needham Virtual Healthcare Conference. Kevin Smith, President and Chief Executive Officer, and Michael Bourque, Chief Financial Officer, are scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 8:45 a.m. Eastern Time. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website,
Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% Company Provides 2025 Growth Outlook Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. "2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, President and Ch
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a strategic collaboration with Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ, "Yuwell"), a global home healthcare medical device manufacturer with a comprehensive portfolio of respiratory products. The strategic collaboration is expected to broaden Inogen's product portfolio through distribution of certain respiratory products in the United States and select other territories, expand and enhance Inogen's innovation pipeline through R&D collaboration, and accelerate the entry of Inogen's brand into the Chines
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth of 4% to 5%. The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting year-over-year growth of 6% exceeding Inogen's previously announced full year 2024 guidance range of $329
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company's ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S. SIMEOX 200 is the next-generation of the original Simeox (currently available in select international markets). It is intended to promote and improve bronchial drainage by enhancing mobilization of bronchial secretions via high frequency oscillatory vibrations and intermittent negative pressure to t
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2024. "We continued to make significant progress on our strategic priorities in the third quarter. Our results demonstrate our team's strong commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "As we move into the fourth quarter, we remain focused on driving growth, continuing innovation, and advancing towards sustainable profitability." Third Quarter 2024 Financial Results Total revenue in the third quarter of 2024 increased 5.8% to $88.8 millio
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
William Blair upgraded Inogen from Mkt Perform to Outperform
JP Morgan downgraded Inogen from Overweight to Neutral and set a new price target of $8.00 from $15.00 previously
Needham downgraded Inogen from Buy to Hold
William Blair downgraded Inogen from Outperform to Mkt Perform
Needham upgraded Inogen from Hold to Buy and set a new price target of $47.00
Stifel reiterated coverage of Inogen with a rating of Hold and set a new price target of $40.00 from $70.00 previously
SVB Leerink reiterated coverage of Inogen with a rating of Market Perform and set a new price target of $42.00 from $72.00 previously
JP Morgan upgraded Inogen from Underweight to Neutral and set a new price target of $45.00 from $71.00 previously
Keybanc downgraded Inogen from Overweight to Sector Weight
William Blair upgraded Inogen from Market Perform to Outperform
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith joins Inogen from Sirtex Medical, where he served as General Counsel and Executive Vice President, Business Development, since 2018. Mr. Smith brings nearly thirty years of experience to the Company. Prior to joining Sirtex, Kevin served as vice president and associate general counsel at Flexion Therapeutics, focusing on securities requirements, business development, and intellectual property. Previously, h
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Michael Bourque as Chief Financial Officer, effective March 4, 2024. Mr. Bourque has served as Treasurer and Chief Financial Officer of Chase Corporation (NYSE:CCF) now owned by KKR & Co. Inc. He succeeds Interim Chief Financial Officer Mike Sergesketter, who will remain in an advisory role during the transition. Mr. Bourque has served as Chief Financial Officer and Treasurer of Chase Corporation since 2021. He also served as Chief Financial Officer of Keystone Dental, Senior Vice President, Chief Financial Officer and Treasu
Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Growth and Organizational Transformation Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Kevin Smith as Inogen's President and Chief Executive Officer and a member of the Board of Directors, effective immediately, succeeding Nabil Shabshab. Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in exe
– Names Mike Sergesketter as Interim Chief Financial Officer– –Reaffirms 2023 Financial Guidance– Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mike Sergesketter as Interim Chief Financial Officer, effective immediately. Mr. Sergesketter last served as Interim Chief Financial Officer of the company between December 2021 and March 2022, and previously served as CFO of Kimball Electronics, Inc. where he was instrumental in helping to develop and execute the company's globalization strategy while also building a robust finance function to support the company's growth. He su
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen's Board of Directors, effective April 1, 2023. The company also announced that Kristen Miranda, who has served as a director since March 2021, will retire as a member of the Board of Directors, effective March 31, 2023. "We are pleased to welcome Tom West to the Inogen Board. Tom brings additional general management and operational experience to the Inogen Board with his history of leadership and business success in medical technology and life sciences healthcare spaces," said Elizabeth Mora, Chairperson of
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Agnes Lee to the position of Senior Vice President of Investor Relations and Strategic Planning, effective May 23, 2022. Nabil Shabshab, President and Chief Executive Officer, said, "I am excited to welcome Agnes to the Inogen team as we continue to strengthen our strategic planning capabilities, further execute against our growth initiatives and communicate our strategy internally and externally, all with the overarching goal of transforming Inogen and driving shareholder value. Agnes brings extensive medical technology and l
Sommetrics, a private company developing products and services to improve sleep health, today released an update on its key accomplishments during the first quarter of 2022. Chief among these accomplishments was the Company's advancing clinical activities aimed at obtaining FDA market clearance for its flagship product, aerSleep® II, that is targeted for the treatment of obstructive sleep apnea in those unable to use standard therapy with continuous positive airway pressure (CPAP) therapy. The self-contained and non-invasive aerSleep device externally applies mild vacuum to the neck to expand the upper airway, eliminating the need for a face mask or tether of any kind. The six-month aerSle
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo
Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% Company Provides 2025 Growth Outlook Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. "2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, President and Ch
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth of 4% to 5%. The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting year-over-year growth of 6% exceeding Inogen's previously announced full year 2024 guidance range of $329
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2024. "We continued to make significant progress on our strategic priorities in the third quarter. Our results demonstrate our team's strong commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "As we move into the fourth quarter, we remain focused on driving growth, continuing innovation, and advancing towards sustainable profitability." Third Quarter 2024 Financial Results Total revenue in the third quarter of 2024 increased 5.8% to $88.8 millio
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Inve
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2024. "I am proud of the performance of our team in the first half of 2024. We have made meaningful progress on our strategic initiatives, driving top-line growth and advancing the profile of the business toward profitability," said Kevin Smith, President and Chief Executive Officer. "We will also continue to advance our innovation pipeline and look forward to delivering best-in-class products to more respiratory patients around the world." Second Quarter 2024 Financial Results Second quarter
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2024 financial results after the market closes on Tuesday, August 6, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Inv
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024. "We are pleased to be off to a solid start at Inogen in 2024. Looking forward, we remain focused on positioning the business for revenue growth, improving our operating discipline to drive long-term profitability, and investing in our innovation pipeline to broaden our product portfolio," said Kevin Smith, President and Chief Executive Officer. "The performance in the quarter reflects the quality of the team we have in place, and we will continue executing against our strategic priorities,
Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2024 financial results after the market closes on Tuesday, May 7, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)